1 Openers of ATP-sensitive K þ channels are of interest in several therapeutic indications including overactive bladder and other lower urinary tract disorders. This study reports on the in vitro and in vivo characterization of a structurally novel naphthylamide N-[2-(2,2,2-trifluoro-1-hydroxy-1-trifluoromethyl-ethyl)-naphthalen-1-yl]-acetamide (A-151892), as an opener of the ATP-sensitive potassium channels. 2 A-151892 was found to be a potent and efficacious potassium channel opener (KCO) as assessed by glibenclamide-sensitive whole-cell current and fluorescence-based membrane potential responses (Àlog EC 50 ¼ 7.63) in guinea-pig bladder smooth muscle cells. respectively, comparable to that of the potencies of the prototypical cyanoguanidine KCO, P1075. The potencies to suppress contractions in thoracic aorta (Àlog IC 50 ¼ 7.81) and portal vein (Àlog IC 50 ¼ 7.98) were not substantially different from those observed for suppression of phasic contractility of the bladder smooth muscle. 5 In vivo, A-151892 was found to potently suppress unstable bladder contractions in obstructed models of unstable contractions in both pigs and rats with pED 35% values of 8.05 and 7.43, respectively. 6 These results demonstrate that naphthylamide analogs exemplified by A-151892 are novel K ATP channel openers and may serve as chemotypes to exploit additional analogs with potential for the treatment of overactive bladder and lower urinary tract symptoms.
1 Openers of ATP-sensitive K þ channels are of interest in several therapeutic indications including overactive bladder and other lower urinary tract disorders. This study reports on the in vitro and in vivo characterization of a structurally novel naphthylamide N-[2-(2,2,2-trifluoro-1-hydroxy-1-trifluoromethyl-ethyl)-naphthalen-1-yl]-acetamide (A-151892), as an opener of the ATP-sensitive potassium channels. 2 A-151892 was found to be a potent and efficacious potassium channel opener (KCO) as assessed by glibenclamide-sensitive whole-cell current and fluorescence-based membrane potential responses (Àlog EC 50 ¼ 7.63) in guinea-pig bladder smooth muscle cells. 4 In pig bladder strips, A-151892 suppressed phasic, carbachol-evoked and electrical field stimulusevoked contractility in a glibenclamide-reversible manner with Àlog IC 50 values of 8.07, 7.33 and 7.02 respectively, comparable to that of the potencies of the prototypical cyanoguanidine KCO, P1075. The potencies to suppress contractions in thoracic aorta (Àlog IC 50 ¼ 7.81) and portal vein (Àlog IC 50 ¼ 7.98) were not substantially different from those observed for suppression of phasic contractility of the bladder smooth muscle. 5 In vivo, A-151892 was found to potently suppress unstable bladder contractions in obstructed models of unstable contractions in both pigs and rats with pED 35% values of 8.05 and 7.43, respectively.
Introduction

K
þ channels play fundamental roles in regulating smooth muscle excitability (Quayle et al., 1997) . In urinary bladder smooth muscle, the roles of various K þ channels including delayed rectifiers, large-and small-conductance Ca 2 þ -activated K þ channels and ATP-sensitive K þ (K ATP ) channels have been widely studied (Herrera et al., 2000; Petkov et al., 2001; Shieh et al., 2001; . K ATP channels together with large-and small-conductance Ca 2 þ -activated K þ channels are critical for the control of myogenic (smooth muscle) tone and excitability (Herrera et al., 2000; . Compounds that selectively open these K þ channels decrease cellular (hyper)excitability, diminish smooth muscle cell activity and could suppress unstable bladder contractions, which may serve as one of the potential etiologies underlying bladder instability (Brading, 1997) .
Of the K þ channel classes, ATP-sensitive K þ channels have received most attention over the years with openers identified from various structural classes including benzopyrans, cyanoguanidines, tertiary carbinols and dihydropyridines, investigated as cardioprotectants and as relaxants of vascular and nonvascular smooth muscle Gopalakrishnan & Shieh, 2004) . More recent molecular and heterologous expression studies have revealed that the K ATP channels are hetero-octameric complexes composed of four inward rectifying K þ channel subunits belonging to Kir6.1 or Kir6.2 that are responsible for ion permeation and four regulatory sulfonylurea receptor (SUR) subunits belonging to the ATP binding cassette superfamily that hosts binding sites for K ATP channel openers including benzopyrans and cyanoguanidines (Babenko et al., 1998; Seino, 1999; Moreau et al., 2000) . Studies from several laboratories have established the relaxant profile of K ATP channel openers as assessed by effects on spontaneous phasic (myogenic), electrical or pharmacologically evoked contractile activity of bladder smooth muscle from a variety of species including humans (Brading, 1997; . Initial evidence for the utility of potassium channel openers (KCOs) for bladder overactivity in humans stemmed from preliminary pilot clinical studies of the benzopyran analogs such as cromakalim where modest effects in symptoms of urinary frequency and mean voided volume were observed (Nurse et al., 1991) . Subsequently, compounds such as the tertiary carbinol ZD6169 and aryl squarate WAY 133537 with modestly improved in vivo selectivity for the urinary bladder relative to benzopyrans such as cromakalim and celikalim have emerged (Howe et al., 1995; Wojdan et al., 1999) . More recently, compounds belonging to the 1.4-dihydropyridine class including A-312110 and A-278637 have been synthesized and characterized Davis-Taber et al., 2003 , Felsch et al., 2004 . In particular, A-278637 was demonstrated to possess enhanced potencies for suppression of unstable bladder contractions vs mean arterial blood pressure effects in an obstructed pig model relative to earlier generation compounds (Brune et al., 2002) .
Although preclinical efforts continue in the exploitation of openers of various potassium channel classes including K ATP , calcium-activated and delayed rectifier K þ channels such as KCNQ heteromers for the potential treatment of overactive bladder, optimally desirable efficacy in preclinical models and degree of separation from undesirable side effects remains unclear Sellers et al., 2001 ). In the case of K ATP channel openers, efforts continue to identify novel chemotypes that may differentially activate K ATP channels in bladder, albeit with the challenging goal of overcoming associated vascular liabilities. In this study, we report the identification and characterization of a structurally novel K ATP channel opener, A-151892 (N-[2-(2,2,2-trifluoro-1-hydroxy-1-trifluoromethyl-ethyl)-naphthalen-1-yl]-acetamide). A-151892 belongs to the naphthylamide series (Turner et al., 2003) , a structure distinct from the chemotypes known thus far. The compound suppressed contractility of the bladder smooth muscle strips with nanomolar affinities comparable to the prototypical cyanoguanidine opener P1075 and showed in vivo efficacy in suppressing unstable bladder contractions. Our studies show that A-151892 may serve as a useful tool to characterize K ATP channels and as a novel chemotype to exploit related analogs with improved bladder vs vascular selectivity.
Methods
Materials
Studies were carried out in accordance with guidelines outlined by the Animal Welfare Act, the Association for Assessment and Accreditation of Laboratory Animals (AAALAC) and the Institutional Animal Care and Use Committee of Abbott Laboratories. Bis-(1,3-dibutylbarbituric acid) trimethine oxonol (DiBAC 4 (3)) was purchased from Molecular Probes (Eugene, OR, U.S.A.). Compounds were prepared in DMSO (Sigma) as a 5 or 10 mM stock, kept protected from light and serial dilutions were prepared in appropriate assay buffer just prior to use.
Membrane potential assays
Functional activity of K ATP channels in guinea-pig bladder smooth muscle cells were assessed as previously described (Gopalakrishnan et al., 1999) by evaluating changes in the membrane potential using the bis-oxonol dye, DiBAC 4 (3), in a 96-well fluorescent imaging plate reader (FLIPR). Briefly, urinary bladders were removed from anesthetized male guineapigs (Hartley, Charles River, Wilmington, MA, U.S.A.) weighing 250-300 g and cells were isolated by enzymatic dissociation. The bladder was chopped into small sections and incubated in Dulbecco's phosphate-buffered saline (Life Technologies, Gaithersburg, MD, U.S.A.) containing 1 mg ml À1 collagenase (type VIII, Sigma, St Louis, MO, U.S.A.) and 0.2 mg ml À1 pronase (Calbiochem, La Jolla, CA, U.S.A.) with continuous stirring at 371C in a cell incubator for 30 min. The mixture was then centrifuged at 1300 Â g for 5 min and the pellet was resuspended in Dulbecco's phosphatebuffered saline and recentrifuged to remove residual enzyme. The cell pellet was resuspended in 5 ml growth media (Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, 100 U ml À1 penicillin, 100 U ml À1 streptomycin and 0.25 mg ml À1 amphotericin B) and dissociated further by pipetting repeatedly through a flame-polished Pasteur pipette and passing it through a polypropylene mesh membrane (Spectrum, Houston, TX, U.S.A.). The cell density was adjusted to 100,000 cells ml À1 by resuspension in growth media and plated in clear-bottomed black 96-well plates for fluorescence studies at a density of 20,000 cells well
À1
. Cells were maintained in a cell incubator with 90% air : 10% CO 2 for 5-7 days. Confluent cells, cultured in black clear-bottomed 96-well plates, were rinsed twice with 200 ml assay buffer (composition, mM: HEPES, 20; NaCl, 120; KCl, 2; CaCl 2 , 2; MgCl 2 , 1; glucose 5; pH 7.4 at 251C) containing 5 mM DiBAC 4 (3) and incubated with 180 ml of buffer in a cell incubator for 30 min to ensure dye distribution across the membrane. Assays were carried out at 371C and were initiated by the addition of various concentrations of the compound. Changes in DiBAC 4 (3) fluorescence were measured at excitation and emission wavelengths of 488 and 520 nm, respectively.
Whole-cell patch clamp studies
Whole-cell patch clamp technique was used to measure changes in ionic currents from bladder smooth muscle cells as previously described (Shieh et al., 2001 Bladder smooth muscle relaxation studies
Bladder strip relaxation studies were performed as previously described (Buckner et al., 2000) . , pH 7.4 at 371C)). The bladder was sectioned after discarding the top dome portion and the lower trigonal area. Approximately 3-5 Â 20-mm strips were prepared from the remaining tissue adjacent to the trigonal area and cut in a circular fashion. The mucosal layer was removed and strips were mounted in 10 ml tissue baths maintained at 371C with one end fixed to a stationary rod and the other to a Grass FT03 transducer at a basal preload of 1.0 g. Tissues were rinsed at 10 min intervals and allowed to equilibrate for at least 70 min.
Spontaneous myogenic phasic activity manifested as transient spikes that varied in frequency, duration and amplitude was observed in many tissues. Tissue strips were exposed to varying concentrations of the test agents for 15 min and changes in contractility were assessed. For electrical field stimulation studies, two parallel platinum electrodes were included and tissues were stimulated using a frequency of 0.05 Hz, 0.5 ms at 20 V. With carbachol-stimulated tissues, the protocol was noncumulative with rinse cycles between each concentration of test compound since the contractile response tended to wane over time. Tissues were pretreated with test compounds for 15 min, exposed to a fixed concentration of carbachol (300 nM, which corresponds to approximately an EC 75 concentration of carbachol) and changes in tension assessed. The tissue was then rinsed for 15 min, and the cycle repeated with another concentration of test compound. Glibenclamide (10 mM) was added at the conclusion of each concentration response curve to assess reversibility of effects.
Vascular tissue relaxation studies
The entire thoracic aorta from male Sprague-Dawley rats (200-350 g) was removed and immediately placed into Krebs Ringer bicarbonate solution. The aorta was cleaned of extraneous tissue, endothelium removed, cut into 3-4 mm rings and mounted in 10 ml isolated tissue baths at 371C. One end was fixed to a stationary glass rod and the other to a Grass FT03 transducer at a basal preload of 1.0 g. Tissues were rinsed every 10 min for a total of 45-60 min. The aorta was primed once with 80 mM KCl rinsed to basal tension and again with phenylephrine (10 mM). Absence of functional endothelium was confirmed by loss of the acetylcholine (10 mM)-induced relaxation. After an additional 60 min equilibration period, tension was established using 25 mM KCl solution and cumulative concentration relaxation response curve was generated for the test compound.
The effects of compounds on myogenic activity of the rat portal vein were assessed as previously described . The portal vein was cleansed of extraneous tissue and mounted in a 10 ml isolated tissue bath at 371C. The portal vein contracted spontaneously with transient spikes that varied in frequency, duration and amplitude. Cumulative concentration response curves were obtained for the test compound with a 15 min exposure time after each addition. Data were recorded on a PowerLab/800 data acquisition system and analyzed as the area under the contractile curve (AUC) for 15 min intervals. Briefly, urinary membranes were prepared from male guineapigs (300-400 g; Charles River, Wilmington, MA, U.S.A.) by homogenization using a Tekmar polytron followed by centrifugation initially at 500 Â g for 10 min and the supernatant subsequently at 40,000 Â g for 30 min at 41C. The membrane pellet was resuspended in ice-cold assay buffer (composition: 139 mM NaCl, 5 mM KCl, 25 mM MgCl 2 , 1.25 mM CaCl 2 and 20 mM HEPES; pH 7.4) for radioligand binding studies. Protein concentrations were determined using bovine serum albumin as a standard (Lowry et al., 1951) .
Membranes (300 mg tube
À1
) were incubated in a total assay volume of 0.25 ml in assay buffer containing an ATP regeneration system (20 mM creatine phosphate, 50 U creatine phosphokinase and 1 mM Na 2 ATP) at 371C for 90 min. In competition experiments, membranes were incubated with varying concentrations of test compounds and with approximately 1 nM of radioligand. Specific radioligand binding was defined by subtracting the nonspecific binding defined by the inclusion of 10 mM unlabeled A-312110 from total binding. Binding was terminated by rapid vacuum filtration through GF/B filters. Filters were washed twice with ice-cold 50 mM Tris-HCl (pH 7.2) and radioactivity bound to the filters was assessed by g-counting at an efficiency of 80% (EG & G Wallac, Gaithersburg, MA, U.S.A.).
Other selectivity studies
A-151892 was evaluated in a binding screen that contained representatives of most G-protein-coupled receptors, and a set of ligand and voltage-gated ion channel binding sites at CEREP (Receptor binding and Enzyme Profile; CEREP, Celle l'Evescault, France).
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Cystometry in obstructed pigs
The method for producing partial outlet obstruction in pigs has been described elsewhere in more detail . Briefly, female Landrace/Yorkshire pigs (B12 weeks old; 14-20 kg) were obstructed with a 7.5-mm silver omega ring placed around the proximal urethra using an inguinal approach. Ring placement was confirmed at necropsy in all animals. At 17-20 weeks after placement of the ring, the pigs were instrumented with telemetry transducer-transmitters (Data Sciences, St Paul, MN, U.S.A.) for the measurement of carotid arterial pressure (unit 1: TA11PA-C40) and intravesical/abdominal pressures (unit 2: TL11M3-D70-PCP).
A port catheter (TI-9, Access Technologies) was placed subcutaneously in the side of the abdomen and its distal catheter was secured in the bladder lumen. Animals were treated with amoxicillin and buprenorphine for 3-5 days postsurgery and allowed to recover for 10-14 days before testing. For urodynamic testing, pigs were anesthetized with a mixture of telazol (4.4 mg kg À1 i.m.) and xylazine (2.2 mg kg À1 i.m.), intubated and maintained on isoflurane/oxygen in the supine position. Anesthesia level and bladder volume (via the port catheter) were adjusted to establish a regular unstable contraction pattern and stable mean arterial pressure (MAP). After a 30 min baseline period, up to two increasing doses of A-151982 were administered intravenously at 30 min intervals. Each dose was administered over a 5 min period.
Cystometry in obstructed rats
Female Sprague-Dawley rats (190-210 g) were anesthetized with halothane and the proximal urethra was ligated using a monofilament ligature as previously described from our laboratory (Fabiyi et al., 2003) . At 4 weeks after obstruction, rats were anesthetized with urethane and the femoral artery and vein were catheterized to measure arterial pressure and to administer test compounds, respectively. Intravesicular pressure was measured using a polyethylene catheter inserted into the apex of the bladder dome. Saline was infused at the rate of 0.1 ml min À1 until a volume was reached that was sufficient to trigger spontaneous nonvoiding contractions but below the threshold for voiding. These spontaneous contractions were allowed to stabilize, after which changes in bladder pressure and MAP were monitored simultaneously for 20 min before and after cumulative intravenous doses of test compound or vehicle.
Data analysis
The concentration dependence of maximal steady-state changes in fluorescence or changes in tension responses was fitted by nonlinear regression analysis (GraphPad Prism, San Diego, CA, U.S.A.) to obtain EC 50 or IC 50 values as appropriate. Spontaneous phasic activity of bladder strips was analyzed for changes in the area under the curve (AUC) of the contractile response during a 15 min interval. For carbacholstimulated responses, values were expressed as percentage of the precontraction responses produced by carbachol. In electrical field-stimulated tissues, the concentration-dependent reduction in the peak amplitude (measured in grams) was used for calculating the EC 50 values. In in vivo studies, data were acquired and analyzed using the Life Science Suite/Po-ne-mah Physiology Platform (Gould Instrument Systems, Valley View, OH, U.S.A.). Bladder contraction amplitude, frequency, duration and area under the bladder pressure curve (AUC) were determined using the Ponemah CYS analysis module. Data from obstructed pigs were averaged over the entire 30 min postdosing period and expressed as percent change from baseline values. In obstructed rats, an increase in bladder pressure over 1 cm H 2 O is considered a contraction and data were averaged over the last 10 min of each period after dosing where bladder effects were maximal. Estimated intravenous doses of each compound required to reduce unstable contraction AUC by 35% values were estimated from the dose-response graphs using GraphPad Prism (GraphPad Software Inc., San Diego, CA, U.S.A.). Data are expressed as mean7s.e.m. When comparing group means, a P-value o0.05 was considered statistically significant.
Results
DiBAC 4 (3) fluorescence responses
A-151892 evoked concentration-dependent decreases in membrane potential as assessed by DiBAC 4 (3) fluorescence changes in guinea-pig bladder smooth muscle cells with a Àlog EC 50 value of 7.6370.10 (EC 50 ¼ 20.3 nM; slope ¼ 1.1470.08; n ¼ 6). When normalized to a prototypical K ATP channel opener, P1075 (for structures, see Figure 1 ), the maximal efficacy, 10373.8%, attained at 1 mM was comparable to that evoked by P1075. As shown in Figure 2 , the responses were attenuated by subsequent addition of glibenclamide (5 mM).
Whole-cell patch clamp measurements
Direct interaction of A-151892 with K ATP channels was studied by whole-cell patch clamp in guinea-pig bladder smooth muscle cells. As shown in Figure 3 , upon addition of A-151892 (10 mM), increases in membrane currents were observed under conditions where the cell was bathed in solution containing 60 mM K þ and voltage clamped at À80 mV with patch pipette containing 140 mM K þ and 0.1 mM ATP. In the presence of A-151892 (10 mM), the membrane current increased from control values of À11.573.3 to À34.573.4 pA. Addition of P1075 (10 mM) did not further enhance K ATP currents. A-151892-evoked current was sensitive to the reversal by 5 mM glibenclamide, suggesting that the compound increases the membrane current by opening K ATP channels in smooth muscle cells. As shown in Figure 2b , A-151892 also hyperpolarized membrane potential in bladder smooth muscle cells, measured under current clamp conditions, in a glibenclamidesensitive manner. 
Displacement of KCO binding
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Bladder strip relaxation
A-151892 evoked a concentration-dependent suppression of spontaneous phasic contractility of pig bladder smooth muscle strips. Addition of 5 mM glibenclamide restored contractile activity ( Figure 5 ). The Àlog IC 50 value of A-151892 calculated by measuring changes in the area under the force integral curve (AUC) was 8.0770.15 (n ¼ 6). Under similar conditions, the Àlog IC 50 value for P1075 was 7.58, which is similar to the value (7.6) previously reported . Contractions evoked by low-frequency electrical stimulation (0.05 Hz, 0.5 ms, 20 V) that reflects presynaptic release principally of both acetylcholine and ATP were also inhibited by A-151892 with Àlog IC 50 ¼ 7.0270.13 and a maximal inhibition of 8776% (n ¼ 6). Likewise, contractions evoked by carbachol were suppressed in a concentration-dependent manner by A-151892 with a Àlog IC 50 value of 7.3370.1 and with a maximal inhibition of 100%. In every case, the inhibition of contractions was reversed by the addition of glibenclamide (5 mM).
Vascular tissue relaxation
To examine interactions with vascular K ATP channels and to contrast this profile with effects on the bladder, the interaction of A-151892 was examined in rat thoracic aorta and portal vein. As depicted in Figure 6 , the compound completely suppressed contractions evoked by 25 mM K þ in aorta (Àlog IC 50 ¼ 7.8170.09; n ¼ 3), whereas those evoked by 80 mM K þ depolarization were relatively insensitive (Àlog IC 50 B4) indicating that the relaxation is mediated via K þ channel-dependent mechanisms. Myogenic contractions in rat portal vein were also suppressed in a concentration- 
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Effect of A-151892 on unstable bladder contractions in obstructed pigs
A-151892 caused dose-dependent inhibition of unstable contractions in anesthetized obstructed pigs. Mean reductions in total contraction AUC of 9.6713, 48.4717.6 and 9671.2% were observed after doses of 3, 10 and 30 nmol kg À1 i.v., respectively. As depicted in Figure 7 , the observed decrease in total area was largely derived by decreases in the contraction frequency. As previously reported in this model with other KCOs (Brune et al., 2002) , contraction duration did not change despite marked decreases in other contraction parameters. For comparative purposes with other KCOs from our laboratory (Brune et al., 2002; Fey et al., 2003) , the dose of compound that suppressed contraction AUC by 35% (AUC pED 35% ) was chosen. The estimated Àlog mol kg À1 dose of A-151892 to inhibit contraction AUC by 35% (AUC pED 35% ) was 8.05 (corresponding to 8.9 nmol kg À1 dose). Under similar conditions, the pED 35% value for P1075 is 8.67 (corresponding to 2.1 nmol kg À1 dose, data not shown).
Effect of A-151892 on unstable bladder contractions in obstructed rats
A-151892 also evoked inhibition of unstable contractions in anesthetized obstructed rats. As shown in Figure 8a , A-151892 (100 nmol kg
À1
) evoked maximal changes in both AUC and MAP at 10-20 min postdosing. The return of the effects to near basal levels at 30 min and beyond may be attributable to the relatively short half-life of the compound. For doseresponse evaluations, data were collected at 10-20 min postdosing. Mean reductions in total contraction AUC of 19.874, 28.878.5 and 75.378.3% were observed after doses of 10, 30 and 100 nmol kg À1 i.v., respectively (n ¼ 6). The estimated Àlog mol kg À1 dose of A-151892 to inhibit contraction AUC by 35% (AUC pED 35% ) was 7.44 (corresponding to 36 nmol kg À1 i.v.).
In vivo selectivity for bladder vs hypotensive effects
The effects on MAP were assessed concurrently with bladder effects in both pig and rat models. In obstructed pigs, A-151892 evoked dose-dependent reductions in MAP with 4.672.1, 22.271.8 and 48.774.2% after doses of 3, 10 and 30 nmol kg À1 i.v., respectively. The MAP ED 10% was 4.6 nmol kg
À1
. At these doses tested, no compensatory increases in heart rate were noted (À1573.9, À1375.8 and À12.273.9% at 3, 10 and 30 nmol kg À1 ), which is consistent with effects of KCOs in this model under isoflurane anesthesia conditions . The estimated bladder selectivity, derived as the ratio of MAP ED 10% vs ED 35% is 0.51, which is in the range previously reported for ZD6169 (0.6) and WAY-133537 (0.5), and some six-fold lower than the dihydropyridine A-278637 in this model (ratio of 3; Brune et al., 2002) . In the obstructed rat model, A-151892 also evoked dose-related decreases in MAP with 0.371.5, 8.772.6 and 28.973.5% after doses of 10, 30 and 100 nmol kg À1 i.v., respectively, and with an estimated MAP ED 10% value of about 30 nmol kg 
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Again, the estimated bladder selectivity ratio of A-151892 is 1.7, in the range previously observed with ZD6169 (1.2) and WAY-133537 (1.1) in this model (Fabiyi et al., 2003) .
Discussion
Overactive bladder in humans is characterized by the symptoms of increased urinary frequency, urgency and/or incontinent episodes. Overactivity associated with the urodynamic finding of involuntary bladder contractions is referred to as bladder instability. Existing pharmacological therapies for overactive bladder include antimuscarinics, which, although widely prescribed, are limited by side effects such as dry mouth. In the light of the fundamental role(s) of K þ channels in governing bladder smooth muscle excitability, openers of these channels serve as an attractive means of dampening smooth muscle excitability, provided such agents are able to selectively activate channels present in bladder smooth muscle vs other smooth muscle particularly in vascular tissues. In the search of chemotypes that activate K ATP channels that may be further exploited, we have identified a structurally novel and potent naphthylamide analog, A-151892 (Turner et al., 2003) . A-151892 evoked concentration-dependent decreases in membrane potential responses and suppressed spontaneous phasic activity of bladder smooth muscle in a glibenclamide-reversible manner. A-151892 also suppressed contractions evoked by muscarinic receptor activation and by electrical field stimulation of bladder smooth muscle strips. Additional evidence for interaction with native K ATP channels was confirmed by whole-cell patch clamp studies, where the compound was efficacious in activating glibenclamide-sensitive currents in isolated bladder smooth muscle cells and by displacement of [ 125 I]A-312110 binding to bladder smooth muscle membranes. Comparison of pharmacological profile of A-151892 across membrane potential, radioligand binding and tissue relaxation assays showed that the compound exhibited potencies and efficacies quite comparable to the prototypical cyanoguanidine KCO P1075 (Table 1) . In vivo, A-151892 effectively suppressed unstable bladder contractions in both pig and rat models of bladder outlet obstruction in a dose-dependent manner.
Membrane potential studies in guinea-pig bladder smooth muscle cells showed that A-151892 evoked concentrationdependent decreases in DiBAC 4 (3) fluorescence. Likewise, A-151892 evoked concentration-dependent suppression of spontaneous phasic activity of pig bladder smooth muscle strips in a glibenclamide-sensitive manner. Comparison of profiles of A-151892 with the prototypical cyanoguanidine opener by fluorescence and tissue relaxation assays showed that A-151892 is about three-to four-fold more potent than P1075, but equiefficacious by these measures. Whole-cell patch clamp studies in bladder smooth muscle cells showed that A-151892 is as efficacious as P1075, albeit at a single maximal concentration, in activating membrane currents or hyperpolarizing the membrane potential. A-151892 also displaced binding of a dihydropyridine K ATP channel opener radioligand [ 125 I]A-312110 to guinea-pig bladder membranes with a Ki value of 39 nM. Previous molecular analysis have revealed the presence of predominantly SUR2B as a component of K ATP channels in bladder smooth muscle from guinea-pig, pig and human (Buckner et al., 2000; Davis-Taber et al., 2000) . Collectively, these observations provides direct evidence that membrane hyperpolarization assessed by DiBAC 4 (3) fluorescence and relaxation of bladder smooth muscle strips are mediated via interaction with the smooth muscle K ATP channels. The lack of significant interaction with high-affinity [ 3 H]glibenclamide binding sites demonstrates selectivity of A-151892 to K ATP channels derived from SUR2-containing subunits. Additionally, lack of significant interaction in radioligand binding and/or functional patch clamp across representatives of most G-protein-coupled receptors as well ligand-and voltage-gated channels further demonstrates the in vitro selectivity of the compound.
A-151892 was potent in suppressing phasic contractility of bladder smooth muscle (IC 50 ¼ 10 nM). In contrast, A-151892 was about 10-fold less potent in suppressing electrically evoked contractions, which is consistent with earlier observations that, in general, K ATP channel openers are about 15-fold more potent in suppressing spontaneous phasic activity than those evoked by electrical field stimulation . The potencies to suppress contractions in thoracic aorta (Àlog IC 50 ¼ 7.81) and portal vein (Àlog IC 50 ¼ 7.98) were not substantially different from those observed for suppression of phasic contractility of the bladder smooth muscle, suggesting .
no in vitro tissue selectivity for A-151892. Interestingly, compared to P0175 that was equipotent in suppressing phasic contractility, low K þ -evoked contractions of aorta and myogenic activity of the portal vein, A-151982 showed about four-fold greater potency to suppress phasic contractility of bladder strips compared to the potencies in vascular tissues.
The in vivo efficacy of A-151892 was examined in both obstructed swine and rat models by evaluating effects on unstable bladder contractions and MAP as described previously (Brune et al., 2002; Fabiyi et al., 2003; Fey et al., 2003) . Comparison of the Àlog ED 35% values to lower AUC of unstable contractions in the pig model showed that A-151892 is substantially more potent than ZD6169 and WAY-133537, but comparable to the potency of the dihydropyridine A-278637 (8.38; Brune et al., 2002) and to the cyanoguanidine P1075 (8.67, this study). Further, the in vitro and in vivo potencies of A-151892 correlate well, which is consistent with the previous observations (Brune et al., 2002) where a good correlation to inhibit myogenic contractions in isolated pig bladder smooth muscle strips vs suppression of unstable bladder contractions in the obstructed pig model was observed.
Although quite generally KCOs cause dose-dependent reductions in MAP, apparent differences as to the extent of hypotension at a given level of bladder contraction inhibition have been previously noted, suggesting differences in bladder selectivity for certain compounds. For example, previous studies using the obstructed pig model have shown that (À)-cromakalim at doses that suppress unstable contractions also substantially decrease MAP, consistent with the lack of selectivity for the first-generation KCOs . The dihydropyridine analog A-278637 has been shown to be five-to six-fold more bladder selective (comparing doses required to decrease contraction AUC by 35% (AUC ED 35% ) vs decrease MAP by 10%, values that enable comparisons across multiple compounds) compared to KCOs such as ZD6169 and WAY-133537 in the obstructed pig model. By the same comparison, the relative bladder selectivity of A-151892 was found to be similar to that previously reported with ZD6169 and WAY-155537, suggesting that this compound does not exhibit superior bladder selectivity. Similar conclusions were derived in the obstructed rat model, where A-151892 effectively suppressed contractions in a dose-dependent manner, but again with bladder vs vascular selectivity comparable to that of ZD6169 and WAY-133537.
Targeting specific K þ channels expressed in bladder smooth muscle cells and/or afferent nerve fibers that control bladder smooth muscle function, or selective partitioning or delivery of drugs into the bladder are some of the approaches that, in principle, offer opportunities for selective modulation of ion channel function. Recent molecular cloning and expression studies have revealed considerable diversity of various K þ channels including calcium-activated K þ channels, KCNQrelated K þ channels (M channels) and ATP-sensitive K þ channels, thereby offering opportunities for selectively targeting subunits present that modulate bladder function. For example, retigabine that opens KCNQ heteromers has been shown to hyperpolarize bladder smooth muscle and inhibit cystometric contractions in rats with experimental bladder instability (Sheldon et al., 2002) . More recently, KW-7158, an opener of transient K þ channels, was shown to depress vesicovascular reflexes as well as xylene-induced bladder hyperactivity, suggesting that this drug affects reflex bladder activity at least in part by depressing afferent pathways (Lu et al., 2002; Sculptoreanu et al., 2004) . With K ATP channels, splice variants of the SUR2 gene -SUR2A vs SUR2B -in cardiac and smooth muscle, respectively, exhibit pharmacological differences. Additional splice variants of both SUR1 and SUR2 genes at the level of exon 17 have been reported (Chutkow et al., 1999; Sakura et al., 1999; Davis-Taber et al., 2000; Hambrock et al., 2002) . For example, a splice variant of SUR1 that lacks exon 17, in combination with Kir6.2, has been shown to form functional K ATP channels with glibenclamide binding and ATP sensitivity similar to the wild-type SUR1 subunit (Hambrock et al., 2002) . With the SUR2 gene, in addition to the C-terminal variants that generate SUR2A and SUR2B, splicing at the level of exon 17, a region close to the nucleotide binding fold NBF-1, has been reported with channels showing modest reductions in ATP sensitivity (Chutkow et al., 1999) . Molecular analyses of K ATP channels in bladder smooth muscle cells have shown that SUR2BD17 variant is the predominant isoform, which interestingly differs from other smooth muscle tissues including the vasculature where SUR2B is the predominant species. Our previous pharmacological analysis showed that K ATP openers from diverse chemically distinct series including the naphthylamide A-151892 were modestly (B4-fold) more potent in opening K ATP channels in cell lines expressing the SUR2BD17/Kir6.2 (Àlog EC 50 ¼ 7.7) compared to the SURB/Kir6.2 (Àlog EC 50 ¼ 7.3) combination (Scott et al., 2004) . Although openers that more substantially differentiate among the two splice forms have not been reported thus far, an agent that preferentially modulates the SUR2BD17 splice variant should, in principle, show enhanced selectivity toward suppressing spontaneous myogenic activity of bladder smooth muscle.
In summary, our present studies show that the naphthylamide analog A-151892 is a novel and potent opener that activates bladder K ATP channels, relaxes bladder smooth muscle and suppresses unstable contractions in obstructed bladders in vivo. A-151892 may serve as a tool to study K ATP channel interactions and serve as an attractive chemotype to further optimize analogs with enhanced bladder vs vascular selectivity with potential for treatment of lower urinary tract disorders including overactive bladder.
